Cryptocurrency Render Rises More Than 5% In 24 hours

Over the past 24 hours, Render's (CRYPTO: RNDR) price has risen 5.62% to $11.29. This continues its positive trend over the past week where it has experienced a 5.0% gain, moving from $10.7 to its current price. As it stands right now, the coin's all-time high is $13.53.

Over the past 24 hours, Render’s (CRYPTO: RNDR) price has risen 5.62% to $11.29. This continues its positive trend over the past week where it has experienced a 5.0% gain, moving from $10.7 to its current price. As it stands right now, the coin’s all-time high is $13.53.

The chart below compares the price movement and volatility for Render over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.

price_chart

The trading volume for the coin has fallen 30.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has decreased 0.28%. This brings the circulating supply to 381.86 million, which makes up an estimated 71.77% of its max supply of 532.07 million. According to our data, the current market cap ranking for RNDR is #32 at $4.29 billion.

supply_and_vol

Powered by CoinGecko API

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

What’s Going On With Candel Therapeutics Stock?

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We recently reported data from the phase 2 randomized clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone," said Paul Peter Tak, MD, PhD, CEO of Candel.

CADL